Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
07:01am, Tuesday, 28'th Jan 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Tuesday, 07'th Jan 2025
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio (GOSS) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 26'th Dec 2024
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Gossamer Bio (GOSS) Rating Upgrade to Buy
01:00pm, Thursday, 21'st Nov 2024
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
10:36am, Friday, 15'th Nov 2024
Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revis
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
10:35am, Thursday, 14'th Nov 2024
The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 11'th Nov 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
07:00pm, Thursday, 07'th Nov 2024
Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:01pm, Monday, 07'th Oct 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
3 Penny Stocks To Buy With Just $50
07:54am, Sunday, 15'th Sep 2024
Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
01:25am, Tuesday, 10'th Sep 2024
Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
06:11pm, Monday, 12'th Aug 2024
Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
02:39pm, Tuesday, 25'th Jun 2024
Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
03:35pm, Thursday, 13'th Jun 2024
Do you have any penny stocks in your portfolio? If you don't, you might want to consider it with any speculative money sitting on the sidelines.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th Jun 2024
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary
